TRAM2 (translocation associated membrane protein 2) is an endoplasmic reticulum (ER) membrane protein essential for collagen type I biosynthesis. Mechanistically, TRAM2 interacts with the ER calcium pump SERCA2b and couples its activity with the translocon, increasing local calcium concentration at collagen synthesis sites to facilitate molecular chaperone function and proper collagen folding 1. Additionally, TRAM2 may act as a ceramide sensor regulating alternative translocation and is required for proper insertion of transmembrane proteins into the ER lumen. Beyond its classical role in collagen synthesis, TRAM2 has emerged as a significant oncogenic factor across multiple cancer types. TRAM2 is overexpressed in glioma, pancreatic cancer, oral squamous cell carcinoma, and osteosarcoma, where it drives malignant progression through multiple mechanisms 2345. In glioma, TRAM2 activates the PI3K/AKT/mTOR signaling pathway to promote proliferation, invasion, migration, and epithelial-mesenchymal transition (EMT) 2. TRAM2 also mediates YAP-induced oncogenic proliferation and cellular invasiveness through FSTL-1 signaling 6. In oral cancer, TRAM2 overexpression correlates with metastasis and lymph node invasion via matrix metalloproteinase activation 4. Therapeutically, targeting TRAM2 suppresses tumor progression and represents a potential treatment strategy. Furthermore, TRAM2 facilitates intracellular Staphylococcus aureus survival through SERCA pump interactions, suggesting host-directed therapeutic potential 7.